Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx

Searching for a bigger spot for itself in the global market weeks after becoming the first Chinese biotech to nab an FDA “breakthrough” designation, BeiGene has enlisted the protein engineers at Ambrx to add some discovery projects to its cancer pipeline.